Core Perspective - Sona Nanotech Inc has initiated its first-in-human clinical trial for its THT therapy aimed at late-stage melanoma patients, marking a significant transition from preclinical to clinical testing [1][2][6] Company Developments - The first patient has been dosed in Santiago, Chile, which is a critical milestone for the company [2][3] - The therapy is classified as a device rather than a drug, designed to enhance tumor visibility to the immune system, potentially leading to tumor shrinkage and improved survival rates [2][4] Clinical Trial Details - The clinical trial will begin with an early feasibility study to assess safety, tolerability, and practical usage of the device, alongside efficacy data [4] - The protocol includes patient check-ins on days 1, 7, 14, 21, and 28, with initial results expected by the end of summer [5] Patient Impact - The therapy aims to help patients who have exhausted other treatment options, focusing on making tumors recognizable to the immune system for potential elimination [6]